Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Larry Glass Insider Profile
4 Followers
Larry Glass, Chief Science Officer at Neuren Pharmaceuticals Limited, holds 21.29M shares in Neuren Pharmaceuticals Limited (Ticker: NURPF). Most recently, Larry Glass Bought $1,290,323 shares of Neuren Pharmaceuticals Limited on Aug 30, 2017 for an estimated value of 80.00K.
Larry Glass has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
Chief Science Officer
Roles that Larry Glass holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Aug 30, 2017 - Aug 30, 2018
Return:-28.60%
The most profitable trade made by Larry Glass
Larry Glass's Trading History
List of latest transactions for each holding click on a transaction to see Larry Glass's performance on stock
You May Also Like
Larry Glass insider profile FAQ
What is the percentage of profitable transactions made by Larry Glass?
The percentage of profitable transactions made by Larry Glass is ―.
What is the average return per transaction made by Larry Glass?
The average return per transaction made by Larry Glass is ―.
What stocks does Larry Glass hold?
Larry Glass holds: NURPF stocks.
What was Larry Glass’s latest transaction?
Larry Glass latest transaction was an Informative Buy of $80.00K.
What was Larry Glass's most profitable transaction?
Larry Glass’s most profitable transaction was an Informative Buy of NURPF stock on August 30, 2017. The return on the trade was -28.60%.
What is Larry Glass's role in Neuren Pharmaceuticals Limited?
Larry Glass's role in Neuren Pharmaceuticals Limited is Chief Science Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.